Baillie Gifford & Co
RXST icon

Baillie Gifford & Co’s RxSight RXST Stock Holding History

Baillie Gifford & Co’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-690,279
Closed -$4.25M – 285
2026
Q1 		$4.25M Sell
690,279
-2,867
-0.4% -$23.8K ﹤0.01% 240
2025
Q4 		$7.22M Buy
693,146
+6,830
+1% +$68.5K 0.01% 228
2025
Q3 		$6.17M Buy
686,316
+217,371
+46% +$1.91M ﹤0.01% 233
2025
Q2 		$6.1M Buy
468,945
+76,714
+20% +$1.15M ﹤0.01% 223
2025
Q1 		$9.9M Sell
392,231
-6,676
-2% -$198K 0.01% 211
2024
Q4 		$13.7M Sell
398,907
-20,097
-5% -$906K 0.01% 200
2024
Q3 		$20.7M Buy
419,004
+60,789
+17% +$3.11M 0.02% 179
2024
Q2 		$21.6M Buy
358,215
+291,733
+439% +$16.7M 0.02% 178
2024
Q1 		$3.43M Buy
+66,482
New +$3.26M ﹤0.01% 244

Other funds holding RXST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.66B AUM 39.91% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Baillie Gifford & Co's RXST Position: Q2 2026 in Review

Baillie Gifford & Co sold out of RxSight (RXST) in Q2 2026, closing a stake of 690,279 shares — an estimated $4.25M sold.

Baillie Gifford & Co first reported a position in RXST in Q1 2024 and held it in 9 quarters. The position peaked at $21.6M in Q2 2024. 151 funds tracked by Wall St. Rank hold RXST as of Q2 2026.

  • Baillie Gifford & Co reported no remaining RxSight position as of Q2 2026 after selling out during the quarter.
  • Baillie Gifford & Co sold 690,279 RxSight shares in Q2 2026, an estimated $4.25M.
  • Baillie Gifford & Co first reported a position in RxSight in Q1 2024 and held it in 9 quarters.
  • Baillie Gifford & Co's RxSight position peaked at $21.6M in Q2 2024.
  • 151 funds tracked by Wall St. Rank held RxSight as of Q2 2026.

Based on Baillie Gifford & Co's 13F filing for Q2 2026, filed 6 Aug 2026.